Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy

View More View Less
  • 1 Department of Neurological Surgery, University of California, San Francisco, California
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

Object. For patients with recurrent glioblastomas multiforme (GBMs) the prognosis is poor. Although chemotherapy may provide a survival advantage, the role of the extent of tumor resection, or the volume of the residual tumor at the time of recurrence, before instituting chemotherapy, is unclear. This study was designed to assess the response to chemotherapy based on the volume of residual disease (VRD) at the start of treatment in patients with recurrent GBMs. To accomplish this, the authors evaluated a homogeneous group of patients with recurrent GBMs who received the same chemotherapeutic agent.

Methods. One hundred nineteen adult patients with recurrent supratentorial GBMs received temozolomide chemotherapy at the time of tumor recurrence. In this cohort the authors analyzed the prognostic significance of volumetrically assessed tumor mass on time to tumor progression (TTP) and survival time (ST).

Multivariate analysis demonstrated that the VRD at the beginning of chemotherapy was a statistically significant predictor of both TTP (p < 0.0001) and ST (p < 0.006) when adjusted for the patient's age, performance score, and time from the initial diagnosis. Patients in whom the VRD was less than 10 cm3 at the start of chemotherapy had a 6-month progression-free survival rate of 32% compared with 8% for patients with a VRD between 10 and 15 cm3 and 3% for patients with a VRD larger than 15 cm3. Patients in whom the VRD was smaller than 10 cm3 had a 1-year survival rate of 37% compared with 9% for patients with a VRD between 10 and 15 cm3 and 18% for patients with a VRD larger than 15 cm3.

Conclusions. These data indicate that patients with recurrent GBMs who start chemotherapy with a smaller volume (< 10 cm3) of residual disease may have a more favorable response to chemotherapy and a more favorable outcome.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1.

    Berger MS, , Deliganis AV, & Dobbins J, et al: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:17841791, 1994 Berger MS, Deliganis AV, Dobbins J, et al: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784–1791, 1994

    • Search Google Scholar
    • Export Citation
  • 2.

    Bower M, , Newlands ES, & Bleehan NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive highgrade glioma. Cancer Chemother Pharmacol 40:484488, 1997 Bower M, Newlands ES, Bleehan NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive highgrade glioma. Cancer Chemother Pharmacol 40:484–488, 1997

    • Search Google Scholar
    • Export Citation
  • 3.

    Brada M, , Hoang-Xuan K, & Rampling R, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259266, 2001 Brada M, Hoang-Xuan K, Rampling R, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259–266, 2001

    • Search Google Scholar
    • Export Citation
  • 4.

    Chow KL, , Gobin YP, & Cloughesy T, et al: Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR 21:471478, 2000 Chow KL, Gobin YP, Cloughesy T, et al: Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR 21:471–478, 2000

    • Search Google Scholar
    • Export Citation
  • 5.

    Coughlin C, , Scott C, & Langer C, et al: Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or ≤ 20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48:13511358, 2000 Coughlin C, Scott C, Langer C, et al: Phase II, two-arm RTOG trial (94–11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or ≤ 20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys 48:1351–1358, 2000

    • Search Google Scholar
    • Export Citation
  • 6.

    Duong DH, , Rostomily RC, & Haynor DR, et al: Measurement of tumor resection volumes from computerized images. Technical note. J Neurosurg 77:151154, 1992 Duong DH, Rostomily RC, Haynor DR, et al: Measurement of tumor resection volumes from computerized images. Technical note. J Neurosurg 77:151–154, 1992

    • Search Google Scholar
    • Export Citation
  • 7.

    Friedman HS, , McLendon RE, & Kerby T, et al: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:38513857, 1998 Friedman HS, McLendon RE, Kerby T, et al: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857, 1998

    • Search Google Scholar
    • Export Citation
  • 8.

    Gilbert MR, , Friedman HS, & Kuttesch JF, et al: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 4:261267, 2002 Gilbert MR, Friedman HS, Kuttesch JF, et al: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 4:261–267, 2002

    • Search Google Scholar
    • Export Citation
  • 9.

    Grant R, , Walker M, & Hadley D, et al: Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol 57:241245, 2002 Grant R, Walker M, Hadley D, et al: Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol 57:241–245, 2002

    • Search Google Scholar
    • Export Citation
  • 10.

    Huncharek M, & Muscat J: Treatment of recurrent high grade astrocytoma: results of a systematic review of 1,415 patients. Anticancer Res 18:13031311, 1998 Huncharek M, Muscat J: Treatment of recurrent high grade astrocytoma: results of a systematic review of 1,415 patients. Anticancer Res 18:1303–1311, 1998

    • Search Google Scholar
    • Export Citation
  • 11.

    Karnofsky DA, & Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer, in MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949, p 196 Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer, in MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949, p 196

    • Search Google Scholar
    • Export Citation
  • 12.

    Keles GE, , Anderson B, & Berger MS: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371379, 1999 Keles GE, Anderson B, Berger MS: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379, 1999

    • Search Google Scholar
    • Export Citation
  • 13.

    Keles GE, , Lamborn KR, & Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735745, 2001 Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735–745, 2001

    • Search Google Scholar
    • Export Citation
  • 14.

    Kowalczuk A, , Macdonald RL, & Amidei C, et al: Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:10281038, 1997 Kowalczuk A, Macdonald RL, Amidei C, et al: Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:1028–1038, 1997

    • Search Google Scholar
    • Export Citation
  • 15.

    Lacroix M, , Abi-Said D, & Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190198, 2001 Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198, 2001

    • Search Google Scholar
    • Export Citation
  • 16.

    Lederman G, , Wronski M, & Arbit E, et al: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155159, 2000 Lederman G, Wronski M, Arbit E, et al: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159, 2000

    • Search Google Scholar
    • Export Citation
  • 17.

    Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council Trial. J Clin Oncol 19:509518, 2001 Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council Trial. J Clin Oncol 19:509–518, 2001

    • Search Google Scholar
    • Export Citation
  • 18.

    Preul MC, , Caramanos Z, & Villemure JG, et al: Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46:306318, 2000 Preul MC, Caramanos Z, Villemure JG, et al: Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46:306–318, 2000

    • Search Google Scholar
    • Export Citation
  • 19.

    Rostomily RC, , Spence AM, & Duong D, et al: Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378388, 1994 Rostomily RC, Spence AM, Duong D, et al: Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378–388, 1994

    • Search Google Scholar
    • Export Citation
  • 20.

    Salcman M: Survival in glioblastoma: historical perspective. Neurosurgery 7:435439, 1980 Salcman M: Survival in glioblastoma: historical perspective. Neurosurgery 7:435–439, 1980

    • Search Google Scholar
    • Export Citation
  • 21.

    Simon JM, , Cornu P, & Boisserie G, et al: Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:6774, 2002 Simon JM, Cornu P, Boisserie G, et al: Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53:67–74, 2002

    • Search Google Scholar
    • Export Citation
  • 22.

    Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:10111018, 2002 Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018, 2002

    • Search Google Scholar
    • Export Citation
  • 23.

    Stupp R, , Dietrich PY, & Ostermann Kralijevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:13751382, 2002 Stupp R, Dietrich PY, Ostermann Kralijevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382, 2002

    • Search Google Scholar
    • Export Citation
  • 24.

    Walker MD, , Green SB, & Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:13231329, 1980 Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329, 1980

    • Search Google Scholar
    • Export Citation
  • 25.

    Yung WK, , Albright RE, & Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588593, 2000 Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593, 2000

    • Search Google Scholar
    • Export Citation
  • 26.

    Yung WK, , Prados MD, & Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:27622771, 1999 Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771, 1999

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 529 132 4
Full Text Views 207 8 4
PDF Downloads 108 7 3
EPUB Downloads 0 0 0